메뉴 건너뛰기
Drugs
Volumn 55, Issue SUPPL. 1, 1998, Pages 10-16
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease
Author keywords

[No Author keywords available]
Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OXIDOPAMINE;
EID: 0031975426     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855001-00002     Document Type: Conference Paper
Times cited : (69)
References (10)
  • 1
    • 73049129373 scopus 로고
    • Der L-3,4 dioxyphenylalanin (=dopa): Effekt bei der parkinson akinese
    • Birkmayer W, Hornykiewicz O. Der L-3,4 dioxyphenylalanin (=dopa): effekt bei der parkinson akinese. Wien Klin Wochenschr 1961; 73: 787-8
    • (1961) Wien Klin Wochenschr , vol.73 , pp. 787-788
    • Birkmayer, W.1    Hornykiewicz, O.2
  • 2
    • 0027500750 scopus 로고
    • Treatment of Parkinson's disease
    • Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993: 329: 1021-7
    • (1993) N Engl J Med , vol.329 , pp. 1021-1027
    • Calne, D.B.1
  • 3
    • 0022365018 scopus 로고
    • Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study
    • Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985; 64: 113-27
    • (1985) J Neural Transm , vol.64 , pp. 113-127
    • Birkmayer, W.1    Knoll, J.2    Riederer, P.3
  • 4
    • 9044227267 scopus 로고
    • Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
    • Lees AJ, on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602-6
    • (1995) BMJ , vol.311 , pp. 1602-1606
    • Lees, A.J.1
  • 5
    • 0001925175 scopus 로고
    • Fluctuations of disability in Parkinson's disease: Pathophysiological aspects
    • Marsden CD, Fahn S, (editors). London: Butterworth
    • Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD, Fahn S, (editors). Movement disorders. London: Butterworth, 1987: 96-122
    • (1987) Movement Disorders , pp. 96-122
    • Marsden, C.D.1    Parkes, J.D.2    Quinn, N.3
  • 6
    • 0024852627 scopus 로고
    • Motor complications associated with chronic levodopa therapy in Parkinson's disease
    • Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989; 39 Suppl. 2: 11-9
    • (1989) Neurology , vol.39 , Issue.2 SUPPL. , pp. 11-19
    • Obeso, J.A.1    Grandas, F.2    Vaamonde, J.3
  • 7
    • 0027131948 scopus 로고
    • Single proton emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease
    • Innis RB, Seibyl JP, Scanley BE, et al. Single proton emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993; 90: 11965-9
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 11965-11969
    • Innis, R.B.1    Seibyl, J.P.2    Scanley, B.E.3
  • 8
    • 0029664364 scopus 로고    scopus 로고
    • 123]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
    • 123]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-7
    • (1996) Neurology , vol.46 , pp. 231-237
    • Marek, K.L.1    Seibyl, J.P.2    Zoghbi, S.S.3
  • 9
    • 0029981856 scopus 로고    scopus 로고
    • 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease
    • 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119: 585-91
    • (1996) Brain , vol.119 , pp. 585-591
    • Morrish, P.K.1    Sawle, G.V.2    Brooks, D.J.3
  • 10
    • 85044494741 scopus 로고
    • Hypothesis: Central mechanisms and levodopa response fluctuations in Parkinson's disease
    • Mouradian MM, Chase TN. Hypothesis: central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988; 11: 585-91
    • (1988) Clin Neuropharmacol , vol.11 , pp. 585-591
    • Mouradian, M.M.1    Chase, T.N.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.